ReviewBiomedicines2022
The Biosynthesis and Medicinal Properties of Taraxerol.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Taraxerol Alleviates Cerebral Ischemia-Reperfusion Induced Inflammation and Ferroptosis via Regulating AKT/NF-κB Pathway.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Natural Products in Gambeya lacourtiana (Sapotaceae): Identification, In Vitro Cytoxicity, and Deep Learning-Based Pharmacokinetic Prediction.Chemistry & biodiversity · 2026Article
- Comparative transcriptome analysis reveals abscisic acid-induced bHLH transcription factors involved in saikosaponin biosynthesis inPlant signaling & behavior · 2025Article
- Integrated Phytochemical and Pharmacological Assessment ofAnalytical science advances · 2025Article
- Resilience of Portulaca plants to environmental stresses and the economic potential of their bioactive compounds.Planta · 2025Review
- Deep transcriptome and metabolome analysis to dissect untapped spatial dynamics of specialized metabolism in Saussurea costus (Falc.) Lipsch.Functional & integrative genomics · 2025Article
- Article
- Review
- Extractives fromPlants (Basel, Switzerland) · 2023Article
- Effects of Taraxerol on Oxidative and Inflammatory Mediators in Isoproterenol-Induced Cardiotoxicity in an Animal Model.Molecules (Basel, Switzerland) · 2023Article
- Determination of Pentacyclic Triterpenoids in Plant Biomass by Porous Graphitic Carbon Liquid Chromatography-Tandem Mass Spectrometry.Molecules (Basel, Switzerland) · 2023Article
- Effect-Directed Profiling ofMolecules (Basel, Switzerland) · 2023Article
- Neuroprotective Properties of Cardoon Leaves Extracts against Neurodevelopmental Deficits in an In Vitro Model of Rett Syndrome Depend on the Extraction Method and Harvest Time.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Taraxerol is a pentacyclic triterpenoid that is actively produced by some higher plants as part of a defense mechanism. The biosynthesis of taraxerol in plants occurs through the mevalonate pathway in the cytosol, in which dimethylallyl diphosphate (DMAPP) and isopentyl pyrophosphate (IPP) are first produced, followed by squalene. Squalene is the primary precursor for the synthesis of triterpenoids, including taraxerol, β-amyrin, and lupeol, which are catalyzed by taraxerol synthase. Taraxerol has been extensively investigated for its medicinal and pharmacological properties, and various biotechnological approaches have been established to produce this compound using in vitro techniques. This review provides an in-depth summary of the hypothesized taraxerol biosynthetic pathway, the medicinal properties of taraxerol, and recent developments on tissue culture for the in vitro production of taraxerol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.